Here are the G-BA decisions from the G-BA meeting held on 7 December 2023 on the early benefit assessments of Entresto, Cosentyx, and Ultomiris.
A complete database of all previous G-BA resolutions is available through my membership.
- Entresto (sacubitril/valsartan); new indication: chronic heart failure with left ventricular dysfunction, patients aged 1 year to 17 years – Additional benefit not proven
- Cosentyx (secukinumab); new indication: Hidradenitis suppurativa (acne inversa) – Additional benefit not proven
- Ultomiris (ravulizumab); new indication: Neuromyelitis optica spectrum disorders, anti-aquaporin-4- IgG seropositive – Additional benefit not proven
Follow me on Instagram to never miss the latest G-BA decisions: